Roche Shares Under Pressure Following Clinical Trial Setback
Roche shares drop after giredestrant fails Phase III breast cancer trial. Analysts diverge on outlook as company pivots…
Roche’s Dividend Milestone Overshadowed by Clinical Trial Setback
Roche’s 39th consecutive dividend increase contrasts with a Phase III trial failure for giredestrant, pressuring shares and clouding…